comparison of the effectiveness of Modafinil and methylphenidate in treatment of excessive daytime sleepiness in patients with Parkinson disease

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220623055257N1

Enrollment

Registered

2022-06-27

Start date

2022-08-23

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Daily-time sleepiness in patients with Parkinson's. Parkinson's disease

Interventions

Intervention 1: Intervention group: 30 patients with Parkinson's disease who are treated with medafinil at a dose of 200 mg daily for 8 weeks to treat daily drowsiness. Intervention 2: Intervention gr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: patients who have Parkinson disease diagnosis of excessive daytime sleepiness(EDS) by neurologist not having sensitivity to Modafinil or Methylphenidate Individual consent to participate in the study

Exclusion criteria

Exclusion criteria: Dissatisfaction of the patient to continue participating in the study history of head trauma diagnosis of other neurological disease such as Dementia thyroid disorder history of CVA drug abuser kidney or liver failure heart disease History of a psychiatric illness being treated with psychiatric medication Taking hypnotics being illiterate

Design outcomes

Primary

Measure	Time frame
Daily sleepiness in patients with Parkinson's. Timepoint: Beginning of study and 8 weeks later. Method of measurement: Epworth Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarzaneh Habibi

Esfahan University of Medical Sciences

fh1390i@yahoo.com+98 31 3792 3071

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026